<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02916732</url>
  </required_header>
  <id_info>
    <org_study_id>C16-08</org_study_id>
    <secondary_id>2016-A00399-42</secondary_id>
    <nct_id>NCT02916732</nct_id>
  </id_info>
  <brief_title>Zika Virus Infection's Pregnancy Consequences in French Department of America</brief_title>
  <acronym>ZIKA-DFA-FE</acronym>
  <official_title>Études Observationnelles Des conséquences de l'Infection à Virus Zika au Cours de la Grossesse Pendant l'épidémie Des départements français d'Amérique de l'année 2016</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Zika (ZIKV) epidemic has spread into the three French Overseas Departments in the&#xD;
      Caribbean (DFAs). It is therefore urgent to set up tools to collect clinical and paraclinical&#xD;
      data for the evaluation of potential complications due to having ZIKV infection during&#xD;
      pregnancy. This study is meant to collect, within usual care practices, clinical and&#xD;
      paraclinical information which will allow the precise description of the consequences of ZIKV&#xD;
      infection occurring during pregnancy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective observational, non-interventional study that has been integrated into&#xD;
      the usual standard of care practices. All information and biological samples collected during&#xD;
      the course of this project will be done through the new medical standard of care which has&#xD;
      been put in place during the ZIKV epidemic in the DFAs; this new standard of care is a result&#xD;
      of existing recommendations from medical professionals and/or public health authorities.&#xD;
      Outside of these recommendations, no invasive procedure will be done simply to satisfy an&#xD;
      objective of this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>9 Months</target_duration>
  <primary_outcome>
    <measure>Incidence of ZIKV infection during pregnancy</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of microcephaly and other fetal abnormalities</measure>
    <time_frame>12 month</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Analysis of risk factor for the occurence of congenital abnormalities</measure>
    <time_frame>12 month</time_frame>
  </other_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">26980</enrollment>
  <condition>Incidence of ZIKV Infection on Fetus During the Pregnancy</condition>
  <arm_group>
    <arm_group_label>Module 1</arm_group_label>
    <description>Identification and monitoring of pregnant women who develop clinical signs of acute infection due to ZIKV (standard monitoring report)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Module 2</arm_group_label>
    <description>Monitoring of pregnant women with a suspected embryofetopathy (standard monitoring report)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Module 3</arm_group_label>
    <description>Trimester biological collection of all pregnant women during the outbreak of Zika (standard monitoring report)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Module 4</arm_group_label>
    <description>Biological collection of maternal blood and cord blood collected during the delivery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Module 5</arm_group_label>
    <description>Biological collection of maternal blood and fetal tissues of pregnant women whose pregnancies started during the outbreak of Zika , ends in an spontaneous abortion, Induced abortion or intrauterine fetal demise</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  bio-bank of serum from all pregnant women.&#xD;
&#xD;
        -  bio-bank of maternal blood and infant cord blood&#xD;
&#xD;
        -  bio-bank of maternal blood and fetal tissues&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The population of this study is women who have been pregnant during the 2016 ZIKV Epidemic&#xD;
        in the DFAs. Five study arms (hereafter called 'modules') have been defined with various&#xD;
        inclusion criteria for each module.&#xD;
&#xD;
        M1: Pregnant women with clinical signs of acute ZIKV infection&#xD;
&#xD;
        Module 2: Pregnant women for which an abnormality has been detected in the fetus.&#xD;
&#xD;
        Module 3: Bio-bank of serum, collected once per trimester, from all pregnant women.&#xD;
&#xD;
        Module 4: Bio-bank of maternal blood and infant cord blood, taken the day of birth in all&#xD;
        mothers and their babies in the 3 DFAs.&#xD;
&#xD;
        Module 5: Bio-bank of maternal blood and fetal tissues from women in whom the pregnancy was&#xD;
        terminated due to miscarriage, abortion on medical grounds, or a fetal death in-utero.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        M1:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  On-going pregnancy regardless the presumed date of birth&#xD;
&#xD;
          -  Clinical signs suggestive of ZIKV infection&#xD;
&#xD;
          -  Whatever the RT-PCR analysis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Minor&#xD;
&#xD;
          -  No consent&#xD;
&#xD;
        M2:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Head circumference &lt; 5th percentile&#xD;
&#xD;
          -  Other brain morphological abnormality&#xD;
&#xD;
          -  Hydramnios&#xD;
&#xD;
          -  Intrauterine growth restriction (IUGR)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Minor&#xD;
&#xD;
          -  No consent&#xD;
&#xD;
        M3:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant woman during epidemic period of ZIKV&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Minor&#xD;
&#xD;
          -  Opposition&#xD;
&#xD;
        M4:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Delivery during epidemic period of ZIKV&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Minor&#xD;
&#xD;
          -  No consent&#xD;
&#xD;
        M5:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Spontaneous abortion or fetal death in utero during epidemic period of ZIKV&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Minor&#xD;
&#xD;
          -  No consent&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bruno Hoen</last_name>
    <email>bruno.hoen@chu-guadeloupe.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CH Andrée Rosemon (CHAR)</name>
      <address>
        <city>Cayenne Cedex</city>
        <zip>97306</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Martinique</name>
      <address>
        <city>Fort de France Cedex</city>
        <zip>97261</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Pointe à Pitre/Les Abymes</name>
      <address>
        <city>Pointe A Pitre</city>
        <zip>97139</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CH de l'Ouest Guyanais Franck Joly (CHOG)</name>
      <address>
        <city>Saint-laurent-du-maroni</city>
        <zip>97320</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>September 26, 2016</study_first_submitted>
  <study_first_submitted_qc>September 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2016</study_first_posted>
  <last_update_submitted>September 26, 2016</last_update_submitted>
  <last_update_submitted_qc>September 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>asymptomatics</keyword>
  <keyword>microcephaly</keyword>
  <keyword>abnormalities</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Zika Virus Infection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

